Immune dysregulation in recurrent in-stent restenosis: mechanisms, biomarkers, and therapy

Recurrent in-stent restenosis (RISR), defined as two or more episodes of luminal renarrowing at the same stent site despite technically successful revascularization, remains among the most intractable problems in contemporary interventional cardiology. It affects a substantial share of patients with multivessel coronary disease and is associated with an approximately two-fold higher adjusted hazard of repeat revascularization than first-time restenosis (adjusted HR 2.09). Conventional models treat restenosis as a largely mechanical phenomenon, yet identical procedural technique and lesion preparation yield divergent outcomes across individuals, implicating biological determinants that current paradigms do not capture. This review examines the evidence that immune dysregulation is a potentially important and therapeutically targetable driver of RISR, with particular emphasis on multivessel disease. We synthesize human biomarker studies, preclinical mechanistic experiments, and clinical trial data into an integrated five-hit model incorporating systemic immune priming, cumulative mechanical injury, biomaterial hypersensitivity, amplified perivascular adipose inflammation, and impaired resolution pathways. Experimental studies indicate that NLRP3 inflammasome activation, endothelial pyroptosis, trained immunity, and T-cell subset imbalance each contribute to neointimal hyperplasia, while translational analyses link routine inflammatory indices, including the systemic immune-inflammation index, albumin-to-globulin ratio, and triglyceride-glucose index, to elevated restenosis risk. Anti-inflammatory trials in unselected cardiovascular populations have produced paradoxical results; we reconcile these disparate outcomes as a function of population selection, endpoint choice, stent era and background therapy, rather than of patient selection alone. On this basis we outline a tiered immunophenotyping strategy spanning routine hematology, flow cytometry, autoantibody and cytokine profiling, and high-dimensional proteomics, and propose an endotype-guided therapeutic algorithm organized around biomarker-directed patient selection, time-limited treatment courses, mechanism-matched agent choice, and structured safety monitoring. The algorithm is a research framework that requires prospective validation. We conclude that endotype-based immunomodulation, rather than indiscriminate anti-inflammatory therapy, is the most credible path toward better outcomes in recurrent restenosis, and that dedicated randomized trials incorporating immune stratification are now the field’s priority.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.2018479
Primary Topic
Coronary Interventions and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune dysregulation in recurrent in-stent restenosis: mechanisms, biomarkers, and therapy

Yusheng Gai, 江建邦, Cancan Gong, Fang Yang et al.
4 links
Frontiers in Immunology
Coronary Interventions and Diagnostics
article

Immune dysregulation in recurrent in-stent restenosis: mechanisms, biomarkers, and therapy

Yusheng Gai, 江建邦, Cancan Gong, Fang Yang, Fei Li
article en

Abstract

Recurrent in-stent restenosis (RISR), defined as two or more episodes of luminal renarrowing at the same stent site despite technically successful revascularization, remains among the most intractable problems in contemporary interventional cardiology. It affects a substantial share of patients with multivessel coronary disease and is associated with an approximately two-fold higher adjusted hazard of repeat revascularization than first-time restenosis (adjusted HR 2.09). Conventional models treat restenosis as a largely mechanical phenomenon, yet identical procedural technique and lesion preparation yield divergent outcomes across individuals, implicating biological determinants that current paradigms do not capture. This review examines the evidence that immune dysregulation is a potentially important and therapeutically targetable driver of RISR, with particular emphasis on multivessel disease. We synthesize human biomarker studies, preclinical mechanistic experiments, and clinical trial data into an integrated five-hit model incorporating systemic immune priming, cumulative mechanical injury, biomaterial hypersensitivity, amplified perivascular adipose inflammation, and impaired resolution pathways. Experimental studies indicate that NLRP3 inflammasome activation, endothelial pyroptosis, trained immunity, and T-cell subset imbalance each contribute to neointimal hyperplasia, while translational analyses link routine inflammatory indices, including the systemic immune-inflammation index, albumin-to-globulin ratio, and triglyceride-glucose index, to elevated restenosis risk. Anti-inflammatory trials in unselected cardiovascular populations have produced paradoxical results; we reconcile these disparate outcomes as a function of population selection, endpoint choice, stent era and background therapy, rather than of patient selection alone. On this basis we outline a tiered immunophenotyping strategy spanning routine hematology, flow cytometry, autoantibody and cytokine profiling, and high-dimensional proteomics, and propose an endotype-guided therapeutic algorithm organized around biomarker-directed patient selection, time-limited treatment courses, mechanism-matched agent choice, and structured safety monitoring. The algorithm is a research framework that requires prospective validation. We conclude that endotype-based immunomodulation, rather than indiscriminate anti-inflammatory therapy, is the most credible path toward better outcomes in recurrent restenosis, and that dedicated randomized trials incorporating immune stratification are now the field’s priority.

Frontiers in ImmunologyVol. 17
Yantaishan Hospital (CN)
Good health and well-being
Coronary Interventions and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon